Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Australia Trade Surplus Beats Forecasts in July as Exports Fall 
Gold Prices Hold Near $4,400 as Fed Rate Hike Bets Ease 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Oil Prices Surge as U.S.-Iran Conflict Threatens Hormuz Supply 
India Services PMI Rises to 54.1 as Hiring Accelerates 
Treasury Yields Set to Stay High as Debt Supply Pressures Bond Market 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
China Services PMI Beats Forecasts as Domestic Demand Improves 
Asian Stocks Rise as Bond Yields Ease, Oil Prices Stabilize 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
OPEC+ Expected to Hold October Oil Output Steady 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Add as a preferred source on Google
Celltrion biopharmaceutical company headquartered in Incheon, South Korea, recently signed a deal with San Jose, California-based biotherapeutics company. They have teamed up to jointly carry out research and development of an oral antibody medicine.
Celltrion and Rani Therapeutics named their project RT-111 and they will work together to create the said drug with ustekinumab which is an autoimmune ingredient. As per Pulse News, the medicine is for oral treatment and mentioned that ustekinumab is being sold under the name of Stelara by Janssen Pharmaceuticals.
This is normally used for treating ulcerative colitis and Crohn’s disease. For this project, the companies will use it to develop an antibody medicine.
The US-based biotherapeutics firm has the technology to turn intravenous and subcutaneous injection-type proteins and antibody therapies into oral medicines. And under the agreement, Celltrion will be supplying its biosimilar CT-P43 referencing Stelara to Rani Therapeutic‘s clinical and non-clinical tests for RT-111.
The deal also states that the latter has a preferential right to develop and bring medicine to the global market. It was noted that ustekinumab has already been approved in the United States so it can be freely used as an ingredient in RT-111.
“We are delighted to be partnering with Celltrion, a leader in biosimilars and biologics manufacturing, on RT-111,” Rani Therapeutics’ chief executive officer, Talat Imran, said in a press release. “This agreement is a validation of our RaniPill oral drug delivery technology, which has already performed well in two separate Phase 1 trial of RT-101 and RT-102, respectively.”
The CEO added, “We value Celltrion as the exclusive provider of ustekinumab biosimilar for our RT-111 program and look forward to sharing the results of our study in due course, and potentially broadening our partnership with Celltrion.”
Celltrion’s head of medical science unit, Kim Sung Hyun, also commented on its new partnership deal with Rani by saying, “Celltrion strives to address unmet needs of patients and partnering with Rani offers the opportunity to replace painful injections with a pill.”
